Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stryker Corp (NY: SYK )

388.52 +2.91 (+0.75%)
Official Closing Price Updated: 4:00 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Stryker Corp

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Baxter Earnings: What To Look For From BAX
Healthcare company Baxter International (NYSE:BAX) will be reporting earnings tomorrow morning. Here’s what investors should know. 
Via StockStory
Analyst Expectations For Stryker's Future
Via Benzinga
Peering Into Stryker's Recent Short Interest
Via Benzinga
What To Expect From Baxter’s (BAX) Q4 Earnings
Healthcare company Baxter International (NYSE:BAX) will be announcing earnings results tomorrow morning. Here’s what investors should know. 
Via StockStory
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Q4 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Boston Scientific (NYSE:BSX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best... 
Via StockStory
$100 Invested In Stryker 10 Years Ago Would Be Worth This Much Today
Via Benzinga
A Glimpse Into The Expert Outlook On Stryker Through 14 Analysts
Via Benzinga
Jim Cramer: This Health Care Stock Is A 'Winner,' Buy Bitcoin Instead Of Coinbase
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” 
Via Benzinga
Stryker (NYSE:SYK) Posts Better-Than-Expected Sales In Q4
Medical technology company Stryker (NYSE:SYK) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.7% year on year to $6.44 billion. Its non-GAAP profit of $4.01 per... 
Via StockStory
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Wall Street analysts upgraded Stryker Corp (NYSE: SYK) after its Q4 report beat expectations, with strong sales and earnings growth projected for 2025. 
Via Benzinga
Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Stryker Earnings Report: Q4 Overview
Via Benzinga
Stryker Earnings Review: Q4 Summary
Via Benzinga
Stryker Earnings Analysis: Q4 Recap
Via Benzinga
Stryker Q4 Earnings Assessment
Via Benzinga
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings
U.S. stock futures were mixed ahead of the crucial earnings from key U.S. technology companies and the Fed's expected pause on rate cuts. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Tesla, Starbucks And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Stryker Undercuts Breakout On Sales Deal, Despite Quarterly Beat
Stryker stock dipped late Tuesday after the medtech company beat forecasts, but announced its plan to divest the U.S. spinal business. 
Via Investor's Business Daily
Insights into Stryker Q4 Earnings
Via Benzinga
Earnings Summary: Stryker Q4
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
Via Benzinga
How Is The Market Feeling About Stryker?
Via Benzinga
Here's How Much You Would Have Made Owning Stryker Stock In The Last 20 Years
Via Benzinga
Earnings Scheduled For January 28, 2025
Via Benzinga
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. 
Via Investor's Business Daily
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
These mid-cap stocks had impressive gains last week, including Inari Medical, Unifirst Corporation, and Walgreens. Are they in your portfolio? 
Via Benzinga
Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position
Stryker acquires Inari Medical in a $4.9 billion deal, enhancing its vascular portfolio with innovative VTE treatments and a growing global reach. 
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Inari Medical Catapults 30% On Rumored Stryker Takeover
Inari is best-known for its series of catheter-like devices that remove blood clots. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.